New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Therapeutic potential of exosomes derived from mesenchymal stem cells for treatment of systemic lupus erythematosus.
Therapeutic potential of exosomes derived from mesenchymal stem cells for treatment of systemic lupus erythematosus. Journal of inflammation (London, England) Samavati, S. F., Yarani, R., Kiani, S., HoseinKhani, Z., Mehrabi, M., Levitte, S., Primavera, R., Chetty, S., Thakor, A. S., Mansouri, K. 2024; 21 (1): 20Abstract
Autoimmune diseases are caused by an imbalance in the immune system, producing autoantibodies that cause inflammation leading to tissue damage and organ dysfunction. Systemic Lupus Erythematosus (SLE) is one of the most common autoimmune diseases and a major contributor to patient morbidity and mortality. Although many drugs manage the disease, curative therapy remains elusive, and current treatment regimens have substantial side effects. Recently, the therapeutic potential of exosomes has been extensively studied, and novel evidence has been demonstrated. A direct relationship between exosome contents and their ability to regulate the immune system, inflammation, and angiogenesis. The unique properties of extracellular vesicles, such as biomolecule transportation, biodegradability, and stability, make exosomes a promising treatment candidate for autoimmune diseases, particularly SLE. This review summarizes the structural features of exosomes, the isolation/purification/quantification method, their origin, effect, immune regulation, a critical consideration for selecting an appropriate source, and their therapeutic mechanisms in SLE.
View details for DOI 10.1186/s12950-024-00381-2
View details for PubMedID 38867277
View details for PubMedCentralID 1447637